Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age
- Chelsea Cieslak
Access Resources
About
This article discusses nirsevimab, its side effects, and its implications for the nursing field. Respiratory syncytial virus (RSV) is a common virus infecting infants, causing many hospitalizations in the US. Previously, palivizumab was the only prevention option, but it had limitations. In 2023, nirsevimab was approved by the FDA for preventing RSV in all infants. It works by stopping RSV from infecting cells. Nirsevimab is expected to lessen the impact of RSV on health and costs.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.